A prospective, multi-center clinical study of apatinib mesylate in the treatment of advanced hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044142

Enrollment

Unknown

Registered

2021-03-11

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

experimental group:apatinib mesylate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years (calculated on the day of signing the informed consent); 2. Patients with hepatocellular carcinoma diagnosed by histopathology and/or cytology; 3. The investigator assessed that the patient could benefit from apatinib treatment; 4. Volunteer to join this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who have been confirmed to be allergic to apatinib mesylate tablets and/or its excipients; 2. Pregnant or breastfeeding women; 3. Except for patients with contraindications to apatinib; 4. Doctors consider not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
PFS;ORR;DCR;OS;DOR;1-year OS rate;	—

Countries

China

Contacts

Public ContactJianbing Wu, Ledu Zhou, Jia Luo

13507917177@163.com+86 13507917177; +86 18773132682; +86 15973189500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026